bluebird bio (BLUE) Shares Gap Up to $175.95
bluebird bio Inc (NASDAQ:BLUE)’s share price gapped up before the market opened on Monday . The stock had previously closed at $168.55, but opened at $175.95. bluebird bio shares last traded at $194.65, with a volume of 2532700 shares changing hands.
A number of brokerages have commented on BLUE. Wells Fargo & Co reissued an “outperform” rating and set a $242.00 target price (up previously from $190.00) on shares of bluebird bio in a report on Tuesday, December 12th. SunTrust Banks increased their target price on bluebird bio to $223.00 and gave the company a “buy” rating in a report on Tuesday, December 12th. Barclays reissued an “overweight” rating and set a $209.00 target price (up previously from $162.00) on shares of bluebird bio in a report on Wednesday, December 13th. Maxim Group cut bluebird bio from a “buy” rating to a “hold” rating and set a $200.00 target price for the company. in a report on Wednesday, December 13th. They noted that the move was a valuation call. Finally, CIBC began coverage on bluebird bio in a report on Thursday, December 21st. They set a “market perform” rating for the company. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $157.45.
The stock has a market capitalization of $8,920.00, a PE ratio of -27.77 and a beta of 2.08.
In other news, COO Susanna Gatti High sold 1,282 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.15, for a total value of $220,696.30. Following the completion of the sale, the chief operating officer now directly owns 13,718 shares in the company, valued at $2,361,553.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Philip D. Gregory sold 2,250 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $172.54, for a total value of $388,215.00. Following the completion of the sale, the insider now owns 28,734 shares of the company’s stock, valued at $4,957,764.36. The disclosure for this sale can be found here. Insiders sold 201,045 shares of company stock valued at $35,817,777 over the last 90 days. Company insiders own 3.90% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Capital Research Global Investors grew its position in bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after acquiring an additional 493,072 shares during the period. Vanguard Group Inc. grew its position in bluebird bio by 10.7% in the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after acquiring an additional 343,856 shares during the period. Eagle Asset Management Inc. purchased a new position in bluebird bio in the third quarter worth approximately $29,539,000. American Century Companies Inc. purchased a new position in bluebird bio in the third quarter worth approximately $31,170,000. Finally, Voya Investment Management LLC grew its position in bluebird bio by 1,251.6% in the second quarter. Voya Investment Management LLC now owns 217,398 shares of the biotechnology company’s stock worth $22,837,000 after acquiring an additional 201,313 shares during the period.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.